KENNETH R HESS to Prognosis
This is a "connection" page, showing publications KENNETH R HESS has written about Prognosis.
Connection Strength
0.538
-
Clinical trial design for microarray predictive marker discovery and assessment. Ann Oncol. 2004 Dec; 15(12):1731-7.
Score: 0.018
-
Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype. Br J Cancer. 2020 10; 123(9):1417-1423.
Score: 0.013
-
Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer. 2020 May 18; 20(1):430.
Score: 0.013
-
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 04; 8(1).
Score: 0.013
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.013
-
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
Score: 0.013
-
Response and progression in recurrent malignant glioma. Neuro Oncol. 1999 10; 1(4):282-8.
Score: 0.013
-
Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center. Ann Surg Oncol. 2019 Oct; 26(11):3593-3599.
Score: 0.012
-
Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol. 1999 May; 42(3):227-31.
Score: 0.012
-
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs. 2019 04; 37(2):345-351.
Score: 0.012
-
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clin Cancer Res. 2018 12 15; 24(24):6594-6610.
Score: 0.012
-
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309.
Score: 0.012
-
Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncol. 2018 Apr 12; 4(4):e175092.
Score: 0.011
-
Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review. J Thorac Cardiovasc Surg. 2018 08; 156(2):847-856.
Score: 0.011
-
Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305.
Score: 0.011
-
Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 01; 28(1):79-87.
Score: 0.011
-
Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2253-61.
Score: 0.011
-
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. J Natl Cancer Inst. 2017 10 01; 109(10).
Score: 0.011
-
Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol. 2017 06 01; 19(6):786-795.
Score: 0.011
-
Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer. 2017 04 01; 123(7):1115-1123.
Score: 0.010
-
Incidental Suspicious Regional Lymph Nodes on Breast Sonography: Is Sampling Necessary? Curr Probl Diagn Radiol. 2017 Mar - Apr; 46(2):100-104.
Score: 0.010
-
Critical Assessment of Clinical Prognostic Tools in Melanoma. Ann Surg Oncol. 2016 09; 23(9):2753-61.
Score: 0.010
-
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin. 2016 09; 66(5):370-4.
Score: 0.010
-
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62.
Score: 0.010
-
Development of a model to predict breast cancer survival using data from the National Cancer Data Base. Surgery. 2016 Feb; 159(2):495-502.
Score: 0.009
-
Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol. 2015 May; 123(1):141-50.
Score: 0.009
-
Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):349-57.
Score: 0.009
-
Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9.
Score: 0.009
-
Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med. 1994 May 30; 13(10):1045-62.
Score: 0.009
-
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8.
Score: 0.009
-
The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol. 2014 Jan; 25(1):276-82.
Score: 0.008
-
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2014 Jan; 16(1):81-91.
Score: 0.008
-
The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):591-9.
Score: 0.008
-
Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. Eur J Cancer. 2012 Sep; 48(13):2066-74.
Score: 0.007
-
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011 Jun 15; 13(3):R67.
Score: 0.007
-
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol. 2011 Nov; 22(11):2387-2393.
Score: 0.007
-
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010 Nov 01; 16(21):5351-61.
Score: 0.007
-
Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther. 2010 May; 9(5):1120-7.
Score: 0.007
-
Abdominal aortic aneurysm. N Engl J Med. 1989 Oct 12; 321(15):1040-2.
Score: 0.006
-
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol. 2009 Sep; 94(2):229-34.
Score: 0.006
-
Prediction of left ventricular ejection fraction using a unique method of chest x-ray and ECG analysis: a noninvasive index of cardiac performance based on the concept of heart volume and mass interrelationship. Am Heart J. 1989 Mar; 117(3):590-8.
Score: 0.006
-
Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol. 2009 Apr 01; 27(10):1592-9.
Score: 0.006
-
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol. 2008 Dec; 10(6):1010-8.
Score: 0.006
-
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008 Apr; 10(2):208-15.
Score: 0.006
-
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1275-81.
Score: 0.006
-
Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6603-9.
Score: 0.006
-
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 2005 Oct 01; 104(7):1468-77.
Score: 0.005
-
Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol. 2005 Oct; 7(4):485-94.
Score: 0.005
-
Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103.
Score: 0.005
-
Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer. 2004 Jul 01; 101(1):58-65.
Score: 0.004
-
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004 Jun; 239(6):818-25; discussion 825-7.
Score: 0.004
-
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93.
Score: 0.004
-
Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):212-21.
Score: 0.004
-
The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003 Aug 15; 9(9):3369-75.
Score: 0.004
-
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15.
Score: 0.004
-
Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology. 2003; 65(3):259-66.
Score: 0.004
-
Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer. 2002 Sep 01; 95(5):1120-6.
Score: 0.004
-
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001 Aug; 95(2):190-8.
Score: 0.004
-
Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro Oncol. 2001 07; 3(3):167-73.
Score: 0.004
-
Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol. 2000 Nov; 17(5):963-9.
Score: 0.003
-
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999 Aug; 17(8):2572-8.
Score: 0.003
-
Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg. 1999 May-Jun; 3(3):263-77.
Score: 0.003
-
Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999 Apr 15; 59(8):1820-4.
Score: 0.003
-
Gamma-ray mutagen sensitivity and survival in patients with glioma. Clin Cancer Res. 1998 Dec; 4(12):3031-5.
Score: 0.003
-
Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res. 1998 Oct; 4(10):2447-54.
Score: 0.003
-
Ependymomas: MIB-1 proliferation index and survival. J Neurooncol. 1998 Oct; 40(1):51-7.
Score: 0.003
-
Unknown primary tumors metastatic to liver. J Clin Oncol. 1998 Jun; 16(6):2105-12.
Score: 0.003
-
Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology. 1998 Mar; 50(3):777-81.
Score: 0.003
-
Pelvic exenteration for locally advanced rectal carcinoma: factors predicting improved survival. Surgery. 1997 May; 121(5):479-87.
Score: 0.003
-
Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol. 1997 May; 15(5):2056-66.
Score: 0.003
-
Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res. 1995 Dec; 1(12):1617-22.
Score: 0.002
-
Effect of pregnancy on prognosis for young women with breast cancer. Lancet. 1994 Jun 25; 343(8913):1587-9.
Score: 0.002
-
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994 Jun; 12(6):1272-80.
Score: 0.002
-
Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. J Vasc Surg. 1986 Mar; 3(3):389-404.
Score: 0.001